11549 RESULTS
COMMENT This is clearly not a good idea. Aside from a far from satisfactory sensitivity and specificity, which leaves far too much room for false-negative and false-positive results, it is also in contrast to what the AD community has always voiced very clearly:
COMMENT Congratulations on a very nice paper confirming in humans what Thomas Wisniewski's and our labs have been study for decades in vitro and in mice, that is, the catalytic activity of apoE4 on amyloid formation and consequent cognitive decline. We and c
COMMENT Much like the research upon exercise and changes in cognitive ability, the at-home testing in research is extremely different from the at-home testing done without research supervision. The presence of a spouse during testing invalidates many, if not most
COMMENT These extremely exciting and important studies provide new information about the time course of proteomic changes associated with predisposition to, and clinical progression of, autosomal dominant Alzheimer’s disease (ADAD) and sporadic AD. The papers ill
COMMENT The proteomics analysis performed in this paper, on CSF collected as part of the DIAN study, is a tour de force. There are a number of intriguing findings. I was very interested by the finding that certain protein levels differed between the mutation carr
COMMENT This ADAD CSF proteomic study is an asset to the AD community as it’s based on a collection of samples over the course of six decades. The authors showed changes in proteins from CSF associated with biomarker and pathological changes of AD. Especially pro
COMMENT This new DIAN study is indeed fascinating. There has been prior research suggesting that glycolytic metabolism is specifically altered early in Alzheimer's disease. What makes studies like these in autosomal-dominant Alzheimer's disease highly i
COMMENT In the age of big data, it has become an almost impossible task to genuinely assess papers reporting on thousands of samples, short of repeating the analyses. Although with resource manuscripts like this, the long-term impact can be difficult to gauge ini
COMMENT Johnson et al. show beautiful analyses of CSF proteomic alterations in relation to estimated year of disease onset (EYO), providing, for the first time, in-depth insight into when, and which, molecular processes are dysregulated in autosomal-dominant AD.
COMMENT This is even more evidence that the key step in anti-amyloid therapy is removal of the existing deposits. Immunotherapy is one of the few anti-amyloid approaches that remove existing deposits in animal models, instead of preventing additional deposits (as
COMMENT The DS and cerebrovascular disease sessions at AAIC showed that both DSAD and ADAD have more CAA than sporadic AD, and it has been suggested that individuals with DSAD have fewer hemorrhages than individuals with APP duplication. In this sense the studies
COMMENT This research of the Ablasser lab nicely explores the role of the cGAS-STING signaling pathway in age-related inflammation with subsequent neuronal damage and memory loss. Interestingly, there is a striking accordance with our recently published paper: Va
COMMENT It was great to hear the talks from Lance Johnson and graduate student Lesley Golden on the APOE4-to-APOE2 “switch mouse” (APOE4s2) model at AAIC in Amsterdam. Although isogenic APOE iPSCs have been established in vitro using the CRISPR gene editing techn
COMMENT Neuroscience in 2022 and 2016, respectively, showed absence of TDP-43 filaments. I saw comments that this may
COMMENT The interest in research on CAA has grown exponentially since the results of multiple clinical trials with anti-Aβ immunotherapy showed that these novel therapies are associated with the development of ARIA. In a sizeable percentage of patients, immunothe
